Travere Therapeutics
Update in progressTVTX (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for rare kidney and metabolic diseases in the United States. Its marketed products include FILSPARI (sparsentan) for IgA nephropathy and Thiola/Thiola EC (tiopronin) for cystinuria. Its clinical programs feature Sparsentan for kidney diseases and Pegtibatinase for classical homocystinuria. The company is based in San Diego, formerly Retrophin.
Company score
- Sentiment
- 0.20
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.07
- Governance
- -0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.11
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!